Anixa Biosciences(ANIX) Prnewswire·2024-07-29 12:45Company Overview - Anixa Biosciences Inc is a clinical-stage biotechnology company focused on the treatment and prevention of cancer [3] - The company's therapeutic portfolio includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center, utilizing a novel CAR-T technology called chimeric endocrine receptor T-cell (CER-T) [3] - Anixa's vaccine portfolio includes breast cancer and ovarian cancer vaccines developed in collaboration with Cleveland Clinic, targeting "retired" proteins expressed in certain cancers [3] - The company partners with world-renowned research institutions to examine emerging technologies for further development and commercialization [3] Technology and Clinical Trials - Anixa's CAR-T technology targets the follicle stimulating hormone receptor (FSHR), found exclusively on ovarian granulosa cells, making it a unique approach known as CER-T therapy [2] - The company will present Phase I clinical trial results of its FSHR-mediated CAR-T therapy for recurrent ovarian cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Global Meeting [1] - The clinical trial presentation will be led by Dr Robert Wenham, Chair of Gynecologic Oncology at Moffitt Cancer Center, Anixa's collaboration partner [1] - The FSHR-mediated CAR-T technology was developed by Dr Jose R Conejo-Garcia at Duke University School of Medicine, with Anixa holding an exclusive worldwide license from The Wistar Institute [2]